A system of relational syllogistic incorporating full Boolean reasoning

We present a system of relational syllogistic, based on classical propositional logic, having primitives of the following form: Some A are R-related to some B; Some A are R-related to all B; All A are R-related to some B; All A are R-related to all B. Such primitives formalize sentences from natural language like `All students read some textbooks'. Here A and B denote arbitrary sets (of objects), and R denotes an arbitrary binary relation between objects. The language of the logic contains only variables denoting sets, determining the class of set terms, and variables denoting binary relations between objects, determining the class of relational terms. Both classes of terms are closed under the standard Boolean operations. The set of relational terms is also closed under taking the converse of a relation. The results of the paper are the completeness theorem with respect to the intended semantics and the computational complexity of the satisfiability problem.Comment: Available at http://link.springer.com/article/10.1007/s10849-012-9165-

Inhibition of caspase-1 prolongs survival of mice infected with rabies virus

Rabies virus infects almost all mammals resulting in lethal disease. To date there is no treatment available for symptomatic rabies and there is an urgent need to develop treatment strategies that would prolong survival, thereby providing a window of opportunity for the host to mount a protective immune response. We hypothesized that both virus and excessive immune response contribute to disease and that interfering with both is necessary to prevent lethal disease. Here, we have inhibited the pro-inflammatory response associated with pyroptosis and showed that inhibition of CASP-1 had a beneficial effect on survival time. Our results confirm that some inflammatory responses may be involved in the pathogenesis of severe disease and the results suggest that effective intervention includes inhibition of virus and host response

Multicore and FPGA implementations of emotional-based agent architectures

The final publication is available at Springer via http://dx.doi.org/10.1007/s11227-014-1307-6.Control architectures based on Emotions are becoming promising solutions for the implementation of future robotic agents. The basic controllers of the architecture are the emotional processes that decide which behaviors of the robot must activate to fulfill the objectives. The number of emotional processes increases (hundreds of millions/s) with the complexity level of the application, reducing the processing capacity of the main processor to solve complex problems (millions of decisions in a given instant). However, the potential parallelism of the emotional processes permits their execution in parallel on FPGAs or Multicores, thus enabling slack computing in the main processor to tackle more complex dynamic problems. In this paper, an emotional architecture for mobile robotic agents is presented. The workload of the emotional processes is evaluated. Then, the main processor is extended with FPGA co-processors through Ethernet link. The FPGAs will be in charge of the execution of the emotional processes in parallel. Different Stratix FPGAs are compared to analyze their suitability to cope with the proposed mobile robotic agent applications. The applications are set up taking into account different environmental conditions, robot dynamics and emotional states. Moreover, the applications are run also on Multicore processors to compare their performance in relation to the FPGAs. Experimental results show that Stratix IV FPGA increases the performance in about one order of magnitude over the main processor and solves all the considered problems. Quad-Core increases the performance in 3.64 times, allowing to tackle about 89 % of the considered problems. Quad-Core has a lower cost than a Stratix IV, so more adequate solution but not for the most complex application. Stratix III could be applied to solve problems with around the double of the requirements that the main processor could support. Finally, a Dual-Core provides slightly better performance than stratix III and it is relatively cheaper.This work was supported in part under Spanish Grant PAID/2012/325 of "Programa de Apoyo a la Investigacion y Desarrollo. Proyectos multidisciplinares", Universitat Politecnica de Valencia, Spain.Domínguez Montagud, CP.; Hassan Mohamed, H.; Crespo, A.; Albaladejo Meroño, J. (2015). Multicore and FPGA implementations of emotional-based agent architectures. Journal of Supercomputing. 71(2):479-507. https://doi.org/10.1007/s11227-014-1307-6S479507712Malfaz M, Salichs MA (2010) Using MUDs as an experimental platform for testing a decision making system for self-motivated autonomous agents. Artif Intell Simul Behav J 2(1):21–44Damiano L, Cañamero L (2010) Constructing emotions. Epistemological groundings and applications in robotics for a synthetic approach to emotions. In: Proceedings of international symposium on aI-inspired biology, The Society for the Study of Artificial Intelligence, pp 20–28Hawes N, Wyatt J, Sloman A (2009) Exploring design space for an integrated intelligent system. Knowl Based Syst 22(7):509–515Sloman A (2009) Some requirements for human-like robots: why the recent over-emphasis on embodiment has held up progress. Creat Brain Like Intell 2009:248–277Arkin RC, Ulam P, Wagner AR (2012) Moral decision-making in autonomous systems: enforcement, moral emotions, dignity, trust and deception. In: Proceedings of the IEEE, Mar 2012, vol 100, no 3, pp 571–589iRobot industrial robots website. http://www.irobot.com/gi/ground/ . Accessed 22 Sept 2014Moravec H (2009) Rise of the robots: the future of artificial intelligence. Scientific American, March 2009. http://www.scientificamerican.com/article/rise-of-the-robots/ . Accessed 14 Oct 2014.Thu Bui L, Abbass HA, Barlow M, Bender A (2012) Robustness against the decision-maker’s attitude to risk in problems with conflicting objectives. IEEE Trans Evolut Comput 16(1):1–19Pedrycz W, Song M (2011) Analytic hierarchy process (AHP) in group decision making and its optimization with an allocation of information granularity. IEEE Trans Fuzzy Syst 19(3):527–539Lee-Johnson CP, Carnegie DA (2010) Mobile robot navigation modulated by artificial emotions. IEEE Trans Syst Man Cybern Part B 40(2):469–480Daglarli E, Temeltas H, Yesiloglu M (2009) Behavioral task processing for cognitive robots using artificial emotions. Neurocomputing 72(13):2835–2844Ventura R, Pinto-Ferreira C (2009) Responding efficiently to relevant stimuli using an emotion-based agent architecture. Neurocomputing 72(13):2923–2930Arkin RC, Ulam P, Wagner AR (2012) Moral decision-making in autonomous systems: enforcement, moral emotions, dignity, trust and deception. Proc IEEE 100(3):571–589Salichs MA, Malfaz M (2012) A new approach to modeling emotions and their use on a decision-making system for artificial agents. Affect Comput IEEE Trans 3(1):56–68Altera Corporation (2011) Stratix III device handbook, vol 1–2, version 2.2. http://www.altera.com/literature/lit-stx3.jsp . Accessed 14 Oct 2014.Altera Corporation (2014) Stratix IV device handbook, vol 1–4, version 5.9. http://www.altera.com/literature/lit-stratix-iv.jsp . Accessed 14 Oct 2014.Naouar MW, Monmasson E, Naassani AA, Slama-Belkhodja I, Patin N (2007) FPGA-based current controllers for AC machine drives: a review. IEEE Trans Ind Electr 54(4):1907–1925Intel Corporation (2014) Desktop 4th generation Intel Core Processor Family, Desktop Intel Pentium Processor Family, and Desktop Intel Celeron Processor Family, Datasheet, vol 1, 2March JL, Sahuquillo J, Hassan H, Petit S, Duato J (2011) A new energy-aware dynamic task set partitioning algorithm for soft and hard embedded real-time systems. Comput J 54(8):1282–1294Del Campo I, Basterretxea K, Echanobe J, Bosque G, Doctor F (2012) A system-on-chip development of a neuro-fuzzy embedded agent for ambient-intelligence environments. IEEE Trans Syst Man Cybern Part B 42(2):501–512Pedraza C, Castillo J, Martínez JI, Huerta P, Bosque JL, Cano J (2011) Genetic algorithm for Boolean minimization in an FPGA cluster. J Supercomput 58(2):244–252Orlowska-Kowalska T, Kaminski M (2011) FPGA implementation of the multilayer neural network for the speed estimation of the two-mass drive system. IEEE Trans Ind Inf 7(3):436–445Cassidy AS, Merolla P, Arthur JV, Esser SK, Jackson B, Alvarez-icaza R, Datta P, Sawada J, Wong TM, Feldman V, Amir A, Ben-dayan D, Mcquinn E, Risk WP, Modha DS (2013) Cognitive computing building block: a versatile and efficient digital neuron model for neurosynaptic cores. In: Proceedings of international joint conference on neural networks, IEEE (IJCNN’2013)IBM Cognitive Computing and Neurosynaptic chips website. http://www.research.ibm.com/cognitive-computing/neurosynaptic-chips.shtml . Accessed 22 Sept 2014Seo E, Jeong J, Park S, Lee J (2008) Energy efficient scheduling of real-time tasks on multicore processors. IEEE Trans Parallel Distrib Syst 19(11):1540–1552Lehoczky J, Sha L, Ding Y (1989) The rate monotonic scheduling algorithm: exact characterization and average case behavior. In: Proceedings of real time systems symposium, IEEE 1989, pp 166–171Ng-Thow-Hing V, Lim J, Wormer J, Sarvadevabhatla RK, Rocha C, Fujimura K, Sakagami Y (2008) The memory game: creating a human-robot interactive scenario for ASIMO. In: Proceedings of intelligent robots and systems, 2008, IROS 2008, IEEE/RSJ international conference, pp 779–78

Combination drug treatment prolongs survival of experimentally infected mice with silver-haired bat rabies virus

Rabies is a lethal disease in humans and animals, killing approximately 60,000 people every year. Currently, there is no treatment available, except post-exposure prophylaxis (PEP) that can be administered whenever exposure to a rabid animal took place. Here we describe the beneficial effects of a combination treatment initiated a

Specific induction of pp125 focal adhesion kinase in human breast cancer

The pp125 focal adhesion kinase (FAK) is involved in integrin-mediated cell signalling and overexpressed in a variety of solid tumours. Focal adhesion kinase expression has been correlated to invasion and metastasis, but the data on breast cancer are inconclusive. We analysed FAK mRNA, protein levels and expression patterns in primary breast cancer and normal breast tissue. FAK expression on the functional protein level and mRNA was determined in 55 matched pairs of breast cancer and corresponding normal tissue by Western blot, immunohistochemistry and RT–PCR. Using a score ranging from 0 to +5 for Western blots, we determined in normal breast tissue a score of 1.51±0.84 (mean±standard deviation), which was strongly induced to 2.91 (±1.22) in breast cancers (P<0.001). Overall, 45 out of 55 tissue pairs (81.8%) showed this upregulation of FAK protein in tumours in comparison to normal tissue. Immunohistochemistry confirmed these findings with a significant higher score for tumours vs physiological tissue (1.0±0.63 vs 2.27±0.91; P=0.001). Interestingly, no overall significant difference in the mRNA levels (P=0.359) was observed. In conclusion, expression levels of the FAK protein are specifically upregulated in breast cancer in comparison to matched normal breast tissue supporting its pivotal role in neoplastic signal transduction and representing a potential marker for malignant transformation

Emerging Technologies for the Detection of Rabies Virus: Challenges and Hopes in the 21st Century

The diagnosis of rabies is routinely based on clinical and epidemiological information, especially when exposures are reported in rabies-endemic countries. Diagnostic tests using conventional assays that appear to be negative, even when undertaken late in the disease and despite the clinical diagnosis, have a tendency, at times, to be unreliable. These tests are rarely optimal and entirely dependent on the nature and quality of the sample supplied. In the course of the past three decades, the application of molecular biology has aided in the development of tests that result in a more rapid detection of rabies virus. These tests enable viral strain identification from clinical specimens. Currently, there are a number of molecular tests that can be used to complement conventional tests in rabies diagnosis. Indeed the challenges in the 21st century for the development of rabies diagnostics are not of a technical nature; these tests are available now. The challenges in the 21st century for diagnostic test developers are two-fold: firstly, to achieve internationally accepted validation of a test that will then lead to its acceptance by organisations globally. Secondly, the areas of the world where such tests are needed are mainly in developing regions where financial and logistical barriers prevent their implementation. Although developing countries with a poor healthcare infrastructure recognise that molecular-based diagnostic assays will be unaffordable for routine use, the cost/benefit ratio should still be measured. Adoption of rapid and affordable rabies diagnostic tests for use in developing countries highlights the importance of sharing and transferring technology through laboratory twinning between the developed and the developing countries. Importantly for developing countries, the benefit of molecular methods as tools is the capability for a differential diagnosis of human diseases that present with similar clinical symptoms. Antemortem testing for human rabies is now possible using molecular techniques. These barriers are not insurmountable and it is our expectation that if such tests are accepted and implemented where they are most needed, they will provide substantial improvements for rabies diagnosis and surveillance. The advent of molecular biology and new technological initiatives that combine advances in biology with other disciplines will support the development of techniques capable of high throughput testing with a low turnaround time for rabies diagnosis

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years